Know Cancer

or
forgot password

Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma


Phase 3
40 Years
N/A
Open (Enrolling)
Female
Endometrial Carcinoma

Thank you

Trial Information

Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma


Inclusion Criteria:



- FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium

- Post menopausal status must be demonstrated

- Signed informed consent

Exclusion Criteria:

- FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the
endometrium

- Younger than 40 or postmenopausal status not established

- Pregnant or breastfeeding

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Changes in Ki67 expression after about 3 weeks of Letrozole treatment for patients with endometrial cancer

Outcome Time Frame:

At time of consent until hysterectomy (generally about 3 weeks)

Safety Issue:

No

Principal Investigator

Lloyd H. Smith, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of California, Davis

Authority:

United States: Institutional Review Board

Study ID:

200917341

NCT ID:

NCT00997373

Start Date:

October 2009

Completion Date:

August 2012

Related Keywords:

  • Endometrial Carcinoma
  • Endometrial Cancer
  • Endometrial Carcinoma
  • Aromatase Inhibitor
  • Letrozole
  • Femara
  • Carcinoma
  • Endometrial Neoplasms
  • Adenoma

Name

Location

University of California, DavisSacramento, California  95818
University of California DavisSacramento, California  95817